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Abstract: Background: Electrochemotherapy is a novel treatment for cutaneous and subcutaneous tumors utilizing 
the combination of electroporation and chemotherapeutic agents. Since tumors have an increasing incidence 
nowadays as a result of environmental and genetic factors, electrochemotherapy could be a promising treatment for 
cancer patients.  
Objective: The aim of this article is to summarize the novel knowledge about the use of electroporation for 
antitumor treatments and to present a new application of electrochemotherapy with a well-known plant derived 
antitumor drug betulinic acid. For the review we have searched the databases of scientific and medical research to 
collect the available publications about the use of electrochemotherapy in the treatment of various types of cancer. 
Method: By the utilization of the available knowledge, we investigated the effect of electroporation on the 
penetration of a topically applied betulinic acid formulation into the skin by ex vivo Raman spectroscopy on hairless 
mouse skin. 
Results: Raman measurements have demonstrated that the penetration depth of betulinic acid can be remarkably 
ameliorated by the use of electroporation, so this protocol can be a possibility for the treatment of deeper localized 
cancer nodules. Furthermore, it proved the influence of various treatment times, since they caused different spatial 
distributions of the drug in the skin. 
Conclusion: The review demonstrates that electrochemotherapy is a promising tool to treat different kinds of 
tumors with high efficiency and with only a few moderate adverse effects. Moreover, it presents a non-invasive 
method to enhance the penetration of antitumor agents, which can offer novel prospects for antitumor therapies. 
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1. INTRODUCTION 
 The transdermal delivery of drugs is an attractive alternative to 
conventional administration routes because it has a lot of 
advantages, like avoiding the hepatic first pass metabolism, the 
degradation in gastrointestinal system; in addition, it is a non-
invasive and patient-friendly method [1-3]. However, because of 
the barrier function of the outermost layer of the skin, the stratum 
corneum, only small and lipophilic molecules are able to penetrate 
through the skin by passive diffusion [4-5]. Moreover, biobarriers 
surrounding the tumor microenvironment present a challenge for 
delivering chemotherapeutics successfully [6]. 
 The numerous technologies developed to enhance the 
penetration of molecules through this barrier have been based on 
various strategies: increasing skin permeability, providing a driving 
force acting on the drug, or the combination of these methods. They 
can be categorized as passive and active approaches [7].  
 Passive penetration enhancers are chemicals that temporarily 
improve the permeability of the stratum corneum therefore they  
 
*Address correspondence to this author at the Department of Pharmaceutical 
Technology, Faculty of Pharmacy, University of Szeged, Eötvös Str. 6, H-6720 
Szeged, Hungary; Tel:+36 62 545 573; Fax: +36 62 545 571;  
E-mail: csanyi@pharm.u-szeged.hu 
facilitate the absorption through the skin. The effects of these 
substances should be provisional and should not influence the 
physiological skin properties.[8] 
 Active penetration enhancements are often physical approaches 
that can cause cavitation, thermal, convective and mechanical 
effects in the skin to enhance drug delivery. Electroporation (EP), 
iontophoresis, ultrasound, laser radiation and photomechanical 
waves, microneedle-based devices, needleless injection, 
magnetophoresis, thermophoresis, radio frequency, suction ablation 
and skin abrasion are all current techniques to improve penetration 
of drugs through the skin [9]. 
 EP works with the application of short, high voltage pulses, 
which cause transitory structural perturbation in the lipid bilayer of 
the membranes, and thus EP can increase transdermal drug delivery 
by several orders of magnitude. This technique can be used to 
deliver drugs, DNA, antibodies, proteins, and fluorescent molecules 
to cells [10].  
 The short (10 µs to 10 ms duration) electric pulses form an 
electric field and when the transdermal voltage reaches 0.5-1 V, 
transient aqueous pathways appear [11]. This pore formation takes 
microseconds while the resealing of the membrane happens in the 
minute time range depending on the used electrical parameters and 
the temperature [12]. The strength of the electric field is ranging 
from 1000 to 5000 V/cm depending on the cell or tissue type [13]. 
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 Electrochemotherapy (ECT) is a modern therapy to treat tumors 
located in the skin, which involves the local application of short, 
high voltage pulses to enhance the intracellular delivery of 
antitumor drugs (Fig. 1). This technique has advantages like high 
effectiveness, safety, limited toxicity, simplicity, cost-effectiveness, 
organ-sparing effect, and suitability for repetitive and neoadjuvant 
treatment [14]. 
 
 
Fig. (1). Mechanism of action of electrochemotherapy. 
 
 For the delivery of pulses to the skin, different types of 
electrodes specific to the application are used: plate, needle, needle-
free microelectrode array and multi-electrode array electrodes. 
Depending on the electrode type, the delivery of the drugs can be 
controlled by the amplitude, the number and the duration of the 
electric pulses [15]. Plate electrodes are placed on the skin surface 
and can be effective in case of superficial nodules, while needle 
electrodes are inserted into the tumor nodule (maximum 3 cm 
depth) and can be used for deeper localized tumors. With this 
electrode design local or general anaesthesia is crucial to prevent 
pain [16].  
 ESOPE (European Standard Operating Procedures of 
Electrochemotherapy), a project to set up the standards for ECT 
advises the use of CliniporatorTM electric pulse generator. The 
electric parameters and the application fields of the various 
electrodes are presented in Table 1 [16, 17]. 
 The first clinical use of EP for cancer treatment was in 1993 
[18] and since then many studies have demonstrated the efficacy of 
this kind of treatment for various kinds of tumors including head 
and neck squamous cell carcinoma, melanoma, basal cell 
carcinoma, adenocarcinoma and Kaposi’s sarcoma [19-24]. In 
comparison to the conventional chemotherapy, ECT causes little or 
no adverse effects. Only slight muscle contractions, oedema and 
erythema occurred during the treatments, but they disappeared 
within 24 hours [25]. 
 The effectiveness of ECT could be explained by multiple 
mechanisms of action besides the increased permeation properties. 
Several studies described vascular reaction after EP treatment [12, 
21, 26-28]. After the pulses, there is hypoperfusion in the treated 
area. This phenomenon is more remarkable for needle electrodes 
than for plate electrodes. This vascular lock can be used effectively 
to avoid washing of the drug within the area of the malignant 
tissues, because the restitution of the reduced blood takes hours in 
tumors, but only minutes in normal tissues [29]. 
 The immunogenic effect of ECT can contribute to the good 
response rates achieved with this technique. It has been shown that 
EP has a weak immunogenic effect by itself but that can be 
increased by the combination of bleomycin with interleukin-2; it 
exhibits a synergistic effect, which could be used to treat systemic 
diseases [12]. 
 Most of the studies regarding ECT have focused on the 
treatment of cutaneous and subcutaneous tumors. Generally, the 
anticancer drugs are administered as an intravenous or intratumor 
bolus injection or infusion and after a few minutes the electric 
pulses are applied to permeabilize the cells to uptake the drugs [25].  
 Several clinical studies approved the efficacy of bleomycin and 
cisplatin treatment in combination with EP in the treatment of 
certain types of skin cancer when administered intravenously or 
intratumorally [30-33]. With the use of EP, the cytotoxicity of 
bleomycin increased 300-5000 fold [30-31] and of cisplatin up to 
80 fold [34].  
 Skin cancer has shown increasing incidence over the past 
decades for various reasons in connection with the increased 
ultraviolet radiation exposure, environmental and genetic factors 
[35]. The three most common types are basal cell and squamous 
cell carcinomas of the skin and cutaneous malignant melanoma [36-
38].  
 Basal cell carcinoma is the most common malignant tumor in 
humans, which accounts for approximately 75 % of all skin cancers 
in the world. Its pathogenesis is associated with non-keratinizing 
cells that originate in the basal layer of the epidermis. Topical 
chemical therapy is used to treat this malignancy with formulations 
like Imiquimod 5 % cream, 5-fluorouracil 5% cream and drugs e.g. 
veniblastin, bleomycin, solasodine glycoalkaoilds, zinc sulfate, 
25 % podophyllin. Physical therapies including light therapy, 
cryotherapy and electrotherapy desiccation are also used in some 
cases. Sharquie et al. demonstrated that topical therapy can be as 
useful as surgical methods in several cases and each therapy should 
be tailored to each patient [39].  
 Each year, 132,000 new cases occur and 65,000 people die 
worldwide from cutaneous malignant melanoma [40]. With the 
standard treatments for melanoma metastases, the response rates 
range from 20-45 % with complete responses less than 5 % [25] in 
comparison with ECT, with which the complete response rates are 
between 60-70 % [14]. According to Heller et al. the complete 
disappearance of tumors after only one ECT treatment was 90 % 
[20]. Kis et al. also achieved remarkable results with the use of 
Table 1. Parameters of the electrodes used with CliniporatorTM. 
- Plate Electrodes Needle Row Electrodes Hexagonal Needle Electrodes 
Arrangement 
2 parallel plates connected to a 
handle  (13 cm) 
Two parallel row arrays of needles connected to 
a handle  (13 cm) 
A hexagonal array of needles connected to a 
handle (13 cm) 
Number of pulses 8 8 96 (8x12 pairs of needles) 
Amplitude over distance ratio 1300 V/cm 1000 V/cm 1000 V/cm 
Pulse duration 100 µs 100 µs 100 µs 
Repetition frequency 1 or 5000 Hz 1 or 5000 Hz 5000 Hz 
Application 
Contact application for the EP of 
exophytic tumors 
Placed into tumor tissue, for smaller infiltrating 
lesions Larger infiltrating tumors 
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ECT for cutaneous metastases of melanoma: objective response 
was 62 % and they reached 23 % complete response rate [41, 42].  
 Monta et al. evaluated the efficacy of ECT in the local 
treatment of stage I-II classic Kaposi’s sarcoma skin localization. 
The complete response rate was 73.6 % after a single ECT 
treatment. They used CliniporatorTM with needle electrodes inserted 
at subcutaneous level or plate electrodes applied onto the skin 
surface of superficial cutaneous lesions. 8-28 minutes after the 
intravenous bleomycin injection, electric pulses were applied for 
40-45 seconds under local or general anesthesia. Because of the fact 
that Kaposi’s sarcoma skin lesions represent challenge for the 
surgeons and ECT treatment achieves high remission, ECT might 
become the “new standard of care” as first line treatment strategy 
for Kaposi’s sarcoma patients [43]. 
 Besides its use for the treatment of cutaneous and subcutaneous 
tumors of any hystotype, researches in the past few years raised 
new applications for ECT in connection with the administration of 
cytotoxic drugs as well (Table 2). 
 A recent study investigated the effect of ECT for the treatment 
of peritoneal micro-metastases using intraoperative fluorescence 
imaging to detect the small tumor lesions. Josserand et al. 
compared the results of when EP or bleomycin was administered 
intravenously alone to that of when bleomycin injection was 
followed by EP (8 pulses, 100 µs at 10 Hz frequency, amplitude 
110 or 130 V, stainless steel non-invasive contact electrodes). In 
mice treated with bleomycin or EP alone, there was no significant 
Table 2. Summary of the last few years’ results in ECT (2013-2016). 
Tumor Type Drug Device Electrode Type 
Electrical 
Parameters Results Reference 
Peritoneal micro-
metastases 
Bleomycin 
intravenously 
S20 generator from 
Betatech (Saint-Orens, 
France) 
Stainless steel non-
invasive contact 
electrodes (1 mm) 
8 pulses 
100 µs 
10 Hz frequency 
amplitude 110 or 
130 V 
Complete response rates 
between 60 and 70% 
Josserand et 
al. [44] 
Pancreatic cancer and 
liver metastases 
Bleomycin 
intravenously - - - 
98.1% of all lesions responded 
to ECT: of the 53 responder 
lesions, 5.7% recurred locally 
and 1.9% showed persistent 
disease after a median follow-
up of 6 months 
Tafuto et al. 
[45] 
Locally advanced 
pancreatic cancer 
Bleomycin 
intravenously  
Needle electrodes 
with linear or 
hexagonal 
configuration 
8-96 pulses 
100 µs duration 
1-5000 Hz frequency  
400-730 V 
910-1000 V/cm 
ECT was well tolerated with 
rapid resolution (mean range 6 
days) of the abdominal pain 
Granata et 
al. [46] 
Tumors of the head 
and neck 
Bleomycin 
intravenously or 
intratumorally or 
cisplatin 
intratumorally 
Cliniporator™ (IGEA 
S.p.A., Italy) 
Plate or needle 
electrodes 
8-96 pulses 
100 µs duration 
5000 Hz frequency 
400-960 V 
38% complete response rate 
Campana et 
al. [17] 
Kaposi’s sarcoma 
stage I-II  
skin localization 
Bleomycin 
intravenously 
Cliniporator™ (IGEA 
S.p.A., Italy) Needle electrodes 
ECT treatment of KS 
cutaneous lesions was 
performed according 
to the ESOPE [16] 
73.6% complete response rate 
Monta et al. 
[43] 
Human ovarian 
carcinoma model 
(in vitro) 
Cisplatin and 5-
fluorouracil 
ECM 830 Square 
Wave Electroporation 
System (manufactured 
by BTX Harvard 
Apparatus) 
Two aluminum 
parallel plates (4 mm 
apart) 
5 pulses 
50 µs duration 
1000-3000 V/cm, 
1 Hz frequency 
ECT showed promising effects 
on both ovarian cell lines with 
recovery of normal Cells 
revealed after 72 hours 
Saczko et al. 
[47] 
Ocular basal cell 
carcinoma 
Bleomycin 
intratumorally 
Cliniporator™ (IGEA 
S.p.A., Italy) 
Four pairs of linear 
needle 
electrodes 
8 square wave pulses  
1000 V/cm  
100 ms duration 
5 kHz frequency 
All 3 lesions underwent a 
complete response 
Salwa et al. 
[49] 
Thyroid papillary 
carcinoma 
Bleomycin 
intravenously 
Cliniporator™ (IGEA 
S.p.A., Italy) 
Needle electrodes 
with hexagonal 
configuration 
100 µs duration 
1000 V 
clinical response was observed 
in all four patients within the 
first 3 weeks after ECT 
Grau et al. 
[50] 
Gastrointestinal 
adenocarcinoma cells Doxorubicin 
ECM 830 Square 
Wave Electroporation 
System (BTX Harvard 
Apparatus, purchased 
from Syngen Biotech, 
Poland) 
Two aluminum plate 
electrodes 
(0.4 cm apart) 
5 rectangular pulses 
1300 V/cm 
50 µs duration 
1 Hz frequency 
EP increased the doxorubicin 
effect to 42% 
EP induced the increase of 
cytotoxicity to 22% in 
LoVoDX cells and to 41% in 
LoVo 
Kulbacka et 
al. [48] 
Merkel cell carcinoma 
bleomycin 
intravenously - - - 
All disease nodules 
disappearing within 2 weeks of 
treatment 
Holdsworth 
and Liew 
[51] 
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difference compared to non-operated mice. In contrast, the survival 
rate of mice treated with ECT increased, and the metastatic load 
decreased. They also observed a twofold reduction in the tumor 
weight when the voltage intensity was higher (130 V as compared 
to 110 V). However, the survival rate of these mice decreased 
significantly indicating the serious side effects due to the too high 
voltage of the electric pulses. That study revealed that ECT can be 
used to treat not only skin cancer, but intraperitoneal metastases too 
[44]. 
 Tafuto et al. demonstrated a new application field for ECT in 
liver metastasis from visceral and deep-seated tumors and in 
pancreatic cancer. The study found this technique effective and 
safe, but stated that this topic needs other studies to confirm the 
results. They recommend ECT, especially for elderly patients 
unsuitable for invasive treatments, because it has minimal side 
effects and potential to treat painful, ulcerated and bleeding lesions 
[45]. 
 Granata et al. also reported the preliminary results of a phase 
I/II study on ECT in the treatment of locally advanced pancreatic 
cancer (LAPC). LAPC is associated with a very low prognosis, and 
current standard treatment is limited to chemotherapy or 
chemoradiotherapy. In this study, ECT with intravenously 
administered bleomycin was performed during open surgery, using 
needle electrodes with linear for smaller or hexagonal configuration 
for larger nodules, operating with 8-96 pulses of 400-730 V and 
910-1000 V/cm, of 100 µs duration, at 1-5000 Hz repetition 
frequency. The results showed no adverse effects or major 
complications, with a good functional result [46].  
 Campana et al. investigated the value of ECT in tumors of the 
head and neck. The treatment procedure was done under mild 
sedation or general anaesthesia with intravenously or intratumorally 
administered bleomycin, or cisplatin, given the tumor. The results 
of the ECT treatment of 39 patients showed 38 % complete 
response rate and the amelioration was higher in case of small (≤ 
2 cm), primary tumors and intratumorally-administered bleomycin. 
The two patients who were given cisplatin intratumorally failed to 
respond to the treatment. They observed only moderate side effects 
with the most serious being ulceration of the skin, mucositis, and 
pain [17]. 
 Saczko et al. investigated a new application field of ECT on a 
human ovarian carcinoma model in vitro with 5-fluorouracil and 
cisplatin. The therapy was performed with parallel plate electrodes 
4 mm apart, with 1000- 3000 V/cm amplitude series, 5 x 50 ms 
impulses in a sequence at the frequency of 1 Hz. Based on the 
results, the authors consider ECT as a promising method for 
treating ovarian cancer, the most lethal type among the 
gynaecological tumors, which has poor prognosis with the current 
conventional chemotherapy [47]. 
 Kulbacka et al. evaluated the EP effect on doxorubicin transport 
efficiency to human multidrug resistant human gastric 
adenocarcinoma cells, which usually show resistance to cytotoxic 
drugs, so conventional chemotherapeutic treatment is ineffective. 
Cell suspension was pulsed 5 times in a cuvette with two 
aluminium plate electrodes with electrical field of 1300 V/cm, pulse 
duration of 50 µs and frequency of 1 Hz. They have found that EP 
increased the doxorubicin effect to 37 % in resistant gastric 
carcinoma cells, 42 % in case of sensitive cells and 22 % in colon 
adenocarcinoma cells. This suggests the application of EP for 
effective cytotoxic drug transport into adenocarcinoma cells, 
especially in cancer patients who do not qualify for radiotherapy or 
chemotherapy with advantages like reduction of drug doses and 
shorter exposure time [48]. 
 Salwa et al. investigated a novel application of ECT on ocular 
basal cell carcinoma treatment. The treatment of the lesions on the 
eyelids were performed with CliniporatorTM: after bleomycin was 
administered intratumorally, 8 square wave pulses with 1000 V/cm 
for 100 ms at 5 kHz were delivered into the tumors with linear 
needle electrodes. All of the 3 patients exhibited a complete 
response. Because of the difficulty due to a paucity of local tissue 
non-surgical options, ECT could be a promising treatment for this 
kind of cancer too [49].  
 Grau et al. studied the effect of ECT on skin metastases of 
papillary thyroid carcinoma (PTC). The treatment protocol 
consisted of intravenous bleomycin injection and application of 
electric pulses of 100 µs and 1000 V administered to the target 
tumor by an electrode under total anaesthesia. Amelioration of all 4 
patients was observed after the first three weeks in the two most 
frequent tumor-derived symptoms: local pain and anxiety. The 
presented results showed that ECT may be an effective choice as 
palliative local therapy in PTC patients with local relapse or skin 
metastases [50]. 
 Holdsworth and Liew showed the success of palliative 
treatment with ECT in an uncontrolled Merkel cell carcinoma: 
four months later there was no evidence of any residual disease 
[51]. 
 Kis et al. presented a case study of three Gorlin-Goltz 
Syndrome patients. The antitumor drug, bleomycin was 
administered intravenously, and CliniporatorTM device was used to 
deliver the pulses. The electrode type for the treatment was selected 
according to the tumor size and type. Only 1 of the 99 treated 
tumors did not show any response, and the complete response rate 
was 87 % during the 2-20-month follow-up period. Because of the 
facial manifestation of the disease, the achieved nice cosmetic 
results are important concomitants for the patients’ satisfaction 
[52]. 
 Balazs et al. demonstrated that the use of EP with a genistein 
nanocarrier system enhances the transdermal penetration and results 
in a rapid and more effective drug transport than the genistein-
based formulation alone [53]. 
 Betulinic acid (BA) is a plant derived drug, a pentacyclic 
lupane-type triterpene, which can be extracted from the bark of the 
birch tree. This drug has anti-inflammatory, in vitro antimalarial, 
anti-HIV and specific antitumor activity. Because of its selective 
toxicity against tumor cells and the fact that normal cells and tissues 
are relatively resistant to it, BA is a promising agent against several 
types of cancer [54-55]. 
 Mechanisms of action of BA are linked to its ability to induce 
apoptotic cell death in cancer cells by triggering the mitochondrial 
pathway of apoptosis. While initial reports suggested that BA is 
selectively cytotoxic against melanoma cell lines, anticancer 
activity was subsequently also reported against other types of 
human cancers including neuroblastoma, glioblastoma, 
medulloblastoma, Ewing tumor, leukaemia as well as several 
carcinomas, i.e. head and neck, colon, breast, hepatocellular, lung, 
prostate, renal cell, ovarian or cervix carcinoma [55].  
 We formulated an ointment of this anticancer agent and 
followed up its penetration in hairless mouse skin with Raman 
spectroscopy. It was determined earlier that the ointment has 
adequate rheological properties and a composition that results in a 
good delivery of the active substance. Ciurlea et al. confirmed the 
activity of topically applied BA in decreasing skin lesions and 
irritation by significantly reducing erythema measured by 
Mexameter [56]. 
 Raman spectroscopy is a widely used method to investigate the 
skin structure and the penetration of drugs [57]. Hairless mouse 
skin is a commonly used model for skin penetration experiments 
[58]. It has advantages like a relatively constant lipid content and a 
SC lipid composition similar to human skin [59]. Hairless mouse 
skin has been found to be an adequate model for human skin [60], 
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its whole thickness is less than a quarter of the human skin 
thickness (2.97 mm vs. 0.70 mm), and the SC thickness is about 
half of it (16.8 µm vs. 8.9 µm) [61]. 
 Our aim was to elaborate a novel, non-invasive ECT method to 
increase the penetration depth and efficacy of the anticancer active 
agent, BA to be able to reach tumors in the deeper regions of the 
skin. 
2. MATERIALS AND METHODS 
2.1. Materials 
 BA was purchased from Cayman Chemical Company (Ann 
Arbor, USA), 2-propanol, isopropyl myristate and PEG 4000 were 
from Merck Kft. (Budapest, Hungary), Transcutol® (diethylene 
glycol monoethyl ether) and Labrasol® (caprylocaproyl 
macrogolglycerides) were obtained from Gattefossé (France). 
2.2. Sample Preparation 
 Our team developed an ointment formulation of 5 % BA for 
topical application for a previous research [56]. The components of 
the cream are listed in Table 3. 
 
Table 3. The composition of the BA containing formulation. 
Compounds of the Ointment 
Betulinic acid 
2-propranol 
Transcutol® 
Isopropyl-myristate 
Labrasol® 
PEG 4000 
 
 BA could be partly dissolved in the mixture of 2-propanol, 
Transcutol®, Isopropyl-myristate and Labrasol®. PEG 4000 was 
melted and homogenized with this suspension. The ointment was 
stirred until cooling. 
2.3. Animal Experiments 
 Six-month-old female SKH-1 hairless mice were housed in a 
thermoneutral environment in plastic cages with a 12 h light-dark 
cycle. They had availability to standard laboratory chow and drink 
water ad libitum. All experiments were in full accordance with the 
NIH guidelines and the interventions were approved in advance by 
the Ethical Committee for the Protection of Animals in Scientific 
Research at the University of Szeged (licence number: 
V./145/2013). 
 Prior to the treatments, the animals were anaesthetized with a 
mixture of ketamine (90 mg (kg bodyweight)−1) and xylazine 
(25 mg (kg bodyweight)−1) administered intraperitoneally. At the 
end of the experiments, the mice were euthanized with an overdose 
of ketamine (300 mg kg−1).  
 The mice involved in the study were divided into 4 groups as 
follows (2 mice were randomly assigned to each group):  
• Group A: Mice treated with dermally applied BA ointment 
for 30 min (conventional treatment). 
• Group B: Mice treated with BA ointment and EP at 900 V 
for 1 min. 
• Group C: Mice treated with BA ointment and EP at 900 V 
for 2 min. 
• Group D: Mice treated with BA ointment and EP at 900 V 
for 6 min. 
 For the conventional treatment (Group A), 0.1 grams of the 
ointment was deposited on the dorsal skin surface of hairless 
mouse, left for 30 minutes for penetration, and after the diffusion 
period the skin surface was cleaned with a dry cotton swab. For the 
EP processes (Group B, C, D) also 0.1 grams of the ointment was 
deposited on the skin, the treatment was performed with the 
headpiece, and then the skin was cleaned as mentioned before. 
 For Raman measurements, at the end of the observation period, 
the animals were sacrificed (as described above) and full-thickness 
skin samples were excised from the treated areas. The samples were 
embedded in Cryomatrix resin (Thermo Fisher Scientific Inc., 
Waltham, MA, USA) and cryosections of 6 µm were made. 
2.4. Instrumentation 
 Raman spectral acquisitions were performed with a Dispersive 
Raman Microscope (Thermo Fisher Scientific Inc., Waltham, MA, 
USA) with an integrated CCD camera and a diode laser operating at 
532 nm. The laser power was set to 10 mW and almost all spectra 
were recorded with a resolution of 4 cm-1. For the measurement of 
BA and BA containing ointment 5 mW laser power and 25 µm 
pinhole aperture were used, to avoid fluorescence of the sample. 
The microspectrometer was equipped with an Olympus microscope 
and all measurements were recorded using a 100x objective. The 
nominal spot size at the sample was assessed to be 2.1 µm. The 
spectral range was 200-3200 cm-1 , the acquisition time of each 
spectrum was 4 x 1s and the slit was usually adjusted to 25 µm. 
Spectral images were obtained using 10 µm steps in X, and 5 µm 
steps in Y lateral directions. Spectral acquisition and pre-processing 
were performed using OMNIC for Dispersive Raman 8.2 software 
(Thermo Electron Scientific Instruments LLC, Madison, WI USA). 
 The skin sections were deposited on aluminium slides, which 
do not give rise to any signal in the spectral region of interest. 
2.5. EP Parameters 
 A Mezoforte Duo Mez 120905-D instrument (Dr. Derm 
Equipment Ltd., Budapest, Hungary) was used to generate the 
electric pulses for the skin EP. The operation of this device is based 
on a pulsed electromagnetic field generated by an amplitude-
modulated sine wave radiofrequency current. The polypropylene-
covered treatment headpiece contains a plate electrode 25 mm in 
diameter indirectly contacting with the treated surface. Modulation 
involves 900 V pulses 5 ms in duration, followed by a 20 ms break. 
Drug transport by means of skin EP can be determined by different 
treatment times (1, 2 or 6 min). 
3. RESULTS AND DISCUSSIONS 
 The effect of EP on the penetration of BA ointment was studied 
in Raman scattering experiments. Raman chemical mapping was 
used to confirm the localization of BA at various skin depths.  
 The first step of our study consisted of establishing the spectral 
features for BA and for the BA containing ointment (Table 4). This 
enabled us to recognize the spectral features of the drug in the 
ointment and in the skin. Fig. (2) depicts the experimental Raman 
spectra of BA, the BA containing ointment, BA-free ointment, and 
the individual components of the ointment in the wavenumber 
range 1550-200 cm-1, to recognize the spectral features of the active 
agent in the ointment formulation. For example, the presence of two 
characteristic peaks for BA (739 and 707 cm-1) confirms the BA 
content of the ointment. 
 However, for the measurements of BA and BA containing 
spectra, we needed to use different parameters, because we 
observed remarkable fluorescence of the drug. BA shows very 
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weak intensity compared to the skin signal, but the observed 
fluorescent signal of the molecule using the above-mentioned 
excitation source can be the indicator of the drug. Untreated skin 
itself does not show fluorescence, so the appearance of this signal 
can be connected to the presence of the active agent (Fig. 3). 
 Raman spectra were acquired from skin treated with BA 
ointment and from non-treated intact ex vivo skin as a control, both 
perpendicular to the SC at equivalent depth and width 
(700x30 µm). 
 Fig. (4) displays qualitative distribution maps of BA in animal 
skin specimens after different EP protocols. It was our aim to 
determine whether the penetration depth of BA can be ameliorated 
with the use of different EP protocols. As the skin sections were 
planar, there was no need for the confocal z-axis and adjustment of 
the depth values. The whole skin thickness of a hairless mouse is 
about 0.7 mm [58, 60], therefore 700 µm deep sections of the skin 
specimen were investigated, corresponding from top to bottom to 
the stratum coneum (5-9 µm [60]) → epidermis (about 29 µm [60]) 
→ dermis.  
Table 4. Assignment of BA vibrations. 
Raman Shift (cm-1) 
BA in Solid State BA Ointment Based on Literature [62] Assignment 
2943 2940 2944 vvs C-H un. stretch 
2871 2876 2875 vs C-H sat. stretch 
1646 - 1646 s C=O stretch 
1449 1449 1451 vs CH3 bend 
- 1394 1400 m C-CH3 bend 
- 1359 1356 m-w COO-stretch 
- - 1320 m CH2 bend 
1232 1231 1232 m mixed, C-H bend, C-C bend, C-O bend 
1198 1198 1195 vs mixed, C-H bend, C-C bend, C-O bend 
1130 1128 1157, 1130 m mixed, C-H bend, C-C bend, C-O bend 
- 1088 1107,1088 m mixed, C-H bend, C-C bend, C-O bend 
- 1046 1043 sh mixed, C-H bend, C-C bend, C-O bend 
983 - 982 m mixed, C-H bend, C-C bend, C-O bend 
945 - 942 m mixed, C-H bend, C-C bend, C-O bend 
916 - 919 m mixed, C-H bend, C-C bend, C-O bend 
- 858 883 w, 856 m υ(C-O-C) 
793 - 789 m C-C bend 
703 703 739 s, 707 s COO-bend 
408 409 406 m O=C-O bend 
 
 
Fig. (2). Experimental Raman spectra of BA (a), BA containing ointment (b), BA-free ointment (c), isopropyl myristate (d), isopropyl alcohol (e), Labrasol® 
(f) and Transcutol® (g). 
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 In order to confirm BA penetration, the chemical maps were 
determined. The characteristic fluorescent signal was used to 
visualize the spatial distribution of BA from the Raman chemical 
mapping. The identification of the active agent present was 
achieved by using a multivariate curve resolution with alternating 
least squares chemometric method. This method provides the 
response profiles of the examined component in complex samples, 
and provides qualitative information about the spatial distribution. 
 The presence of the fluorescent signal due to BA in the skin 
indicates the distribution of betulinic acid following conventional 
treatment.  This signal is weak and almost all of the upper layers of 
the skin are affected (Fig. 4A). Without EP, the epidermal and 
upper dermal regions serve as a tight barrier limiting the diffusion 
of BA. Thus, a slow and lower amount diffusion of BA took place. 
After 1 min 900 V EP treatment, BA penetration was remarkably 
deeper and showed better distribution approximately in the whole 
skin section (Fig. 4B). The BA content of the skin specimen (to a 
depth of 700 µm) was relatively lower after the 900 V 2 min EP 
treatment, mostly present in the upper layers of the epidermis and 
the deeper regions (Fig. 4C). After 6 min 900 V treatment, the drug 
disappears from the upper layers and is present in the undermost 
layers of the dermis, indicating the penetration to deeper regions, 
and presumably potential to systematic absorption (Fig. 4D). 
CONCLUSION 
 ECT can be a novel opportunity in cancer treatment, which is 
confirmed by numerous researches and increasing numbers of 
clinical studies. This therapy has many beneficial properties like 
reduced drug doses, negligible side effects, high efficiency; 
however in most of the cases it is at least a minimally invasive 
process because of the electrode arrangement.  
 This study has demonstrated a non-invasive ECT treatment, 
investigating the effect of EP on the penetration of a plant-derived 
antitumor drug, BA incorporated in an ointment formulation. The 
penetration of the drug was studied in hairless mouse skin with 
Raman measurements. The study revealed that EP increases the 
penetration of BA into the skin, and after a 6-min treatment, a 
 
Fig. (3). Experimental Raman spectra of non-treated hairless mouse skin (a) and the fluorescent spectra of BA-treated skin (b). 
 
 
 
Fig. (4). Qualitative Raman maps of BA distribution in animal skin specimens following different EP protocols. Conventionally treated skin as control (a), 
skin treated with EP at 900 V for 1 min (b), for 2 min (c) and for 6 min (d).  
Colour coding of content: red>yellow>green>blue. 
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significant amount of the drug reached the undermost layers of 
dermis.  
 The results presented in this work demonstrated that the 
combination of EP and BA can be a promising opportunity to treat 
tumors in the deeper skin regions in a non-invasive way. 
 Even though our conclusions are potentially auspicious for the 
clinical application of EP for anticancer drug delivery, a number of 
questions remain to be clarified before human therapy can be 
initiated. 
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